Rituximab in Interstitial Pneumonitis

Summary

Rituximab in Interstitial Pneumonitis is a clinical trial^[1].

Key Facts

• Rituximab in Interstitial Pneumonitis is in the country of Netherlands^[2].
• Rituximab in Interstitial Pneumonitis's instance of is recorded as clinical trial^[3].
• Rituximab in Interstitial Pneumonitis's start time is recorded as +2014-09-30T00:00:00Z^[4].
• Rituximab in Interstitial Pneumonitis's end time is recorded as +2017-10-31T00:00:00Z^[5].
• Rituximab in Interstitial Pneumonitis's contributor to the creative work or subject is recorded as VU University Medical Center^[6].
• Rituximab in Interstitial Pneumonitis's main subject is recorded as pneumonia^[7].
• Rituximab in Interstitial Pneumonitis's number of participants is recorded as {'unit': '1', 'amount': '+20'}^[8].
• Rituximab in Interstitial Pneumonitis's title is recorded as Rituximab in Life Threatening Therapy Resistant Progressive Interstitial Pneumonitis^[9].
• Rituximab in Interstitial Pneumonitis's short name is recorded as RITUX-IP^[10].
• Rituximab in Interstitial Pneumonitis's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[11].
• Rituximab in Interstitial Pneumonitis's ClinicalTrials.gov ID is recorded as NCT02251964^[12].
• Rituximab in Interstitial Pneumonitis's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+70'}^[13].
• Rituximab in Interstitial Pneumonitis's research intervention is recorded as rituximab^[14].
• Rituximab in Interstitial Pneumonitis's clinical trial phase is recorded as phase II clinical trial^[15].
• Rituximab in Interstitial Pneumonitis's clinical trial phase is recorded as phase III clinical trial^[16].
• Rituximab in Interstitial Pneumonitis's research site is recorded as Catholic University of Applied Social Sciences^[17].
• Rituximab in Interstitial Pneumonitis's study type is recorded as interventional study^[18].